CytomX Therapeutics announced that management will participate in three major healthcare investor conferences in September 2026, including Wells Fargo, Cantor Global Healthcare, and Morgan Stanley conferences. The company will host fireside chats and one-on-one investor meetings at these events. Live webcasts will be available on CytomX's website.

CytomX Therapeutics expanded its collaboration with Regeneron Pharmaceuticals to develop conditionally-activated bispecific cancer therapies combining CytomX's PROBODY platform with Regeneron's Veloci-Bi platform. CytomX will receive $37 million for two additional programs, with potential total milestones reaching approximately $4 billion across up to 6 additional future targets.

CytomX Therapeutics announced that management will participate in the Jefferies Global Healthcare Conference on June 4, 2026, and the Goldman Sachs 47th Annual Global Healthcare Conference on June 10, 2026. The company will host fireside chats and one-on-one investor meetings at both events. CytomX is a clinical-stage biopharmaceutical company developing conditionally activated masked PROBODY therapeutics for oncology, with lead candidates including varsetatug masetecan (Varseta-M) for colorectal cancer and CX-801 for melanoma.

The article compares small-cap and megacap healthcare stocks, using CytomX Therapeutics and Johnson & Johnson as examples. Small-cap stocks like CTMX offer higher growth potential but carry significant risk with no approved drugs and substantial losses. Megacap stocks like JNJ provide stability, consistent revenue growth, and dividend payments, though with lower explosive upside potential. The choice depends on individual investment goals and risk tolerance.

CytomX Therapeutics priced a $250 million underwritten public offering of 45.99 million shares at $5.30 per share and pre-funded warrants. The company plans to use net proceeds for development of Varseta-M and other pipeline programs. The offering is expected to close on March 19, 2026.

CytomX Therapeutics announced that management will participate in two upcoming conferences in February 2026: the Guggenheim Emerging Outlook Biotech Summit on February 11 in New York and World ADC London on February 25 in London. The clinical-stage biopharmaceutical company, focused on conditionally activated biologics for oncology, continues to advance its pipeline including varsetatug masetecan and CX-801.

CytomX Therapeutics, a clinical-stage oncology-focused biopharmaceutical company, announced upcoming presentations of its clinical-stage pipeline including CX-2051 and CX-801, with Phase 1 data updates expected in early 2026.

CytomX Therapeutics will report its third quarter financial results on November 6, 2025, after market close, followed by a conference call and webcast at 5:00 p.m. ET.

Multiple healthcare stocks experienced significant price movements during Thursday's after-market trading session, with some companies seeing notable gains while others experienced declines.

CytomX Therapeutics reported Q2 2025 results with declining revenue, reduced operating expenses, and positive clinical pipeline progress, particularly for its lead colorectal cancer candidate CX-2051.

Calidi Biotherapeutics is developing a groundbreaking genetic medicine platform using engineered viruses to precisely target and treat metastatic cancers, with promising preclinical data presented at AACR and ASCO conferences.

CytomX Therapeutics and Moderna presented preclinical data on an mRNA-encoded masked IL-12 molecule, which showed potent anti-tumor activity with enhanced tolerability.